Sign in
CompletedPhase 1

A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9

Key facts

Who runs it
Oslo University Hospital Hf
Where
Norway1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 1
People taking part
30 people enrolled
Started
11 Sept 2023
Ended
13 Apr 2026
Type of study
Interventional
Record updated
22 June 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

Where is this trial?

It has sites in one country. Choose a country to see its sites.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
22 June 2026